Rhumbline Advisers raised its position in PRA Health Sciences, Inc. (NASDAQ:PRAH) by 48.5% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 44,149 shares of the medical research company’s stock after acquiring an additional 14,413 shares during the period. Rhumbline Advisers owned approximately 0.07% of PRA Health Sciences worth $3,312,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Meeder Asset Management Inc. boosted its stake in PRA Health Sciences by 144.0% in the second quarter. Meeder Asset Management Inc. now owns 1,535 shares of the medical research company’s stock valued at $115,000 after acquiring an additional 906 shares in the last quarter. Envestnet Asset Management Inc. boosted its stake in PRA Health Sciences by 232.3% in the first quarter. Envestnet Asset Management Inc. now owns 1,844 shares of the medical research company’s stock valued at $121,000 after acquiring an additional 1,289 shares in the last quarter. Ameritas Investment Partners Inc. acquired a new stake in PRA Health Sciences in the first quarter valued at approximately $136,000. CAPROCK Group Inc. acquired a new stake in PRA Health Sciences in the second quarter valued at approximately $208,000. Finally, Aperio Group LLC acquired a new stake in PRA Health Sciences in the second quarter valued at approximately $233,000. Institutional investors own 98.38% of the company’s stock.

TRADEMARK VIOLATION WARNING: “PRA Health Sciences, Inc. (PRAH) Holdings Raised by Rhumbline Advisers” was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece on another website, it was illegally copied and reposted in violation of United States & international copyright & trademark law. The original version of this piece can be accessed at https://www.thecerbatgem.com/2017/09/08/pra-health-sciences-inc-prah-holdings-raised-by-rhumbline-advisers.html.

PRA Health Sciences, Inc. (NASDAQ:PRAH) opened at 77.40 on Friday. The firm has a market capitalization of $4.85 billion, a P/E ratio of 49.97 and a beta of 0.45. PRA Health Sciences, Inc. has a 52-week low of $49.29 and a 52-week high of $80.99. The company’s 50-day moving average is $75.77 and its 200-day moving average is $69.62.

PRA Health Sciences (NASDAQ:PRAH) last posted its earnings results on Monday, August 7th. The medical research company reported $0.62 EPS for the quarter, missing the Zacks’ consensus estimate of $0.72 by $0.10. The company had revenue of $457.90 million during the quarter, compared to analysts’ expectations of $447.79 million. PRA Health Sciences had a net margin of 5.15% and a return on equity of 21.17%. The company’s quarterly revenue was up .5% on a year-over-year basis. During the same period last year, the business earned $0.63 earnings per share. On average, analysts predict that PRA Health Sciences, Inc. will post $3.19 EPS for the current year.

In related news, CEO Colin Shannon sold 400,000 shares of the stock in a transaction on Monday, August 14th. The shares were sold at an average price of $74.85, for a total transaction of $29,940,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, VP Linda Baddour sold 100,000 shares of the stock in a transaction on Monday, August 14th. The stock was sold at an average price of $74.85, for a total transaction of $7,485,000.00. The disclosure for this sale can be found here. In the last quarter, insiders have sold 10,000,000 shares of company stock valued at $748,500,000. 2.10% of the stock is owned by company insiders.

Several equities research analysts have weighed in on the stock. Raymond James Financial, Inc. assumed coverage on shares of PRA Health Sciences in a research note on Wednesday, August 16th. They issued an “outperform” rating and a $89.00 target price for the company. Citigroup Inc. reiterated a “buy” rating and set a $90.00 price objective (up from $73.00) on shares of PRA Health Sciences in a research note on Wednesday, June 28th. Zacks Investment Research downgraded shares of PRA Health Sciences from a “buy” rating to a “hold” rating in a research note on Thursday. SunTrust Banks, Inc. reiterated a “buy” rating on shares of PRA Health Sciences in a research note on Wednesday, August 9th. Finally, Robert W. Baird lifted their price objective on shares of PRA Health Sciences from $82.00 to $83.00 and gave the stock an “outperform” rating in a research note on Tuesday, August 8th. One analyst has rated the stock with a hold rating and eleven have assigned a buy rating to the stock. PRA Health Sciences presently has a consensus rating of “Buy” and an average target price of $85.00.

About PRA Health Sciences

PRA Health Sciences, Inc is a contract research organization. The Company provides outsourced clinical development services to the biotechnology and pharmaceutical industries. The Company offers therapeutic services in areas of pharmaceutical development, including oncology, central nervous system, inflammation and infectious diseases.

Institutional Ownership by Quarter for PRA Health Sciences (NASDAQ:PRAH)

Receive News & Stock Ratings for PRA Health Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences Inc. and related stocks with our FREE daily email newsletter.